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A b s t r a c t  
This article reviews in-vitro modeling of the release kinetics of hydrophobic drugs encapsulated by 
polymeric materials. Major continuum models along with their assumptions and limitations for 
micron-sized systems will be considered.  The dependence on the swelling and degradation for such 
systems will also be discussed. As polymer micelles have gained popularity in the past decades, 
applications and limitations of continuum models to such nano-sized systems will be examined.  A 
different approach based on molecular dynamics simulation will be introduced.  
Keywords: Diffusion, Continuum models, Swelling, Degradation, Micelles, Molecular dynamics 
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Introduction  
Polymers have been used as drug carrier systems for several 
decades.All polymers used in practice are biodegradable[1-5]. This 
is because non-degradable polymers cannot be easily eliminated 
from the patientÊs body upon the consumption of the drugs. 
Therefore, such polymers are not used in practice.  However, 
polymers that exhibit long degradation time (longer than the time 
scale of the drug release) are usually considered as „non-
degradable‰ from the drug kinetics perspective as the molecular 
weights of such polymers do not change during the release 
process. Figure 1 and Figure 2 show a few „non-biodegradable‰ 
and biodegradable polymer structures that are commonly used as 
drug delivery systems. Figure 3 (a) and (b) show the drug carrier 
systems in which the drug is encapsulated by polymer in a 
spherical geometry. Different geometries (e.g., cylindrical) can be 
used but they exhibit different release kinetics even though the 
same polymer is used. The effect of the device geometry on drug 
release kinetics will be discussed later. Since such systems are 
usually micron-sized, continuum models are found suitable for 
describing the corresponding kinetics. Figure 3 (c) shows a carrier 
system that is made up of polymeric micelles.  In fact, this type of 
carrier system has become quite popular in recent years as such 
nanometer-size systems offer longer circulation times[6-9]. Such 
micelles are formed from individual amphiphilic polymer chains that 
spontaneously form nano-sized aggregates in selective solvents 
(water in the case of drug delivery systems) above a threshold 
concentration called the critical micelle concentration (CMC). This 
is due to the good solubility of one and poor solubility of the other 
block of the copolymer in the selected solvent [10]. These 
polymeric micelles are usually tens of nanometers in size. They are 
characterized by their unique core-shell structure, in which the core 
is composed of hydrophobic blocks that are surrounded by a 
palisade of hydrophilic blocks. Generally, the hydrophobic core 
acts as a micro reservoir for the solubilization of hydrophobic drugs 
while the hydrophilic shell provides stealth properties. However, 
their release kinetics differs significantly from that of the micron-
sized carriers and it is conceivable that continuum models may not 
be applicable. 
 
 
Figure 1.Chemical structures of „non-biodegradable‰ polymers used for drug delivery. The first structure from the left is urethane links and the 
second structure is polydimethylsiloxane. 
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Figure 2.Chemical structures of biodegradable polyesters: (a) poly(lactide), (b) poly(glycolide) and (c) poly(ē-caprolactone). 
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Figure 3. Schematic representation of a) micron-sized non-biodegradable polymer, b) micron-sized biodegradable polymer and c) nano-
sized polymeric micelle system. 
Obviously, the chemical structure of the polymer used in the 
aforementioned carriers will play a significant role in determining 
the total amount of drug released over a given period of time (i.e., 
release profile) which will in turn affect the in vivo pharmacokinetics 
parameters (e.g., clearance, half-life, etc.).All of the 
aforementioned polymer carrier systems can be administered via 
oral or intravenously. Recently, a great deal of attention has 
focused on the development of controlled release drug delivery 
systems that are administrated intravenously.  It is desirable to 
have the total concentration of drug last longer in the bloodstream 
so that multiple dosages for patients are not required. When 
comparing single dose to multiple dose administration of drugs, a 
single dose has been proven to be a more cost-effective alternative 
so far.  
It is worth noting that the decrease in drug concentration in blood is 
attributed to two factors: distribution of the drug to targeted and 
non-targeted tissues and elimination of the drug by kidney or 
metabolism. The distribution of the drug to the tissues occurs at a 
much faster rate compared to its elimination process.  Figure 4 
shows a typical drug concentration vs. time curve from a 
pharmacokinetic experiment on micron-sized polymer drug 
carriers. During the distribution process, the concentration of the 
drug in bloodstream decreases considerably because a high 
percentage of the drug distributes to different tissues. Later, 
equilibrium in the drug concentration will then be established 
between the tissues and the blood stream. 
The elimination process occurs to micron-sized carriers.  However, 
if the polymer carrier systems have sizes in the range of 10nm ă 
400nm, the elimination rate can be significantly decreased[6-
9].Obviously, the most ideal situation is that the carriers are only 
distributed to the target tissues and there is no elimination. 
Regardless micron-sized or nano-sized carriers, it is obvious that 
drugs exhibiting required diffusivity in the polymer are most 
desirable. The intent of this review paper is to discuss different in-
vitro mathematical models as well as their usages and limitations. 
 
 
 
Figure 4.A typical drug concentration profile in blood after intravenous administration of drug. The drug concentration is at the highest level 
shortly after the intravenous injection at t~0 (C0) and decreases during the distribution and elimination phases. The distribution phase includes 
distribution of drug to targeted and non-targeted tissues. 
c) 
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Continuum Models for Micron-Sized Carriers 
Continuum models were first developed to describe the release 
kinetics of drug encapsulated in a micron-sized polymer film.  Such 
models are essentially developed for in vitro environment by 
including various effects such as concentration gradient, swelling, 
and degradation of polymer. Later, researchers developed micron-
sized continuum models to describe kinetics of drug encapsulated 
in devices with different geometries such as thin films, spheres and 
cylinders. Three types of micron-sized drug carriers will be 
discussed and they are non-biodegradable, swollen, and 
biodegradable polymers. 
The advantages and disadvantages of micron-sized continuum 
models used to describe drug delivery kinetics will be discussed 
respectively for thin films, spheres and cylinder geometries for 
each drug delivery device in the following sections. 
Non-Biodegradable Polymeric Carriers 
As mentioned, mathematical models developed for this type of 
polymers are essentially used for biodegradable polymers 
exhibiting long times for complete degradation. In other words, the 
degree of degradation is negligible relative to the release time 
scale. With these types of polymers, water molecules tend to 
diffuse into these systems causing swelling which results in 
diffusion of drug molecules out through the swollen polymer matrix. 
Five decades ago, Professor Higuchi was the first one to lay the 
foundation for quantitative analysis of drug release from polymer 
matrices. He proposed a simple thin film model based on a 
pseudo-steady state assumption for the release of drug from an 
ointment using simple mass balance concept and FickÊs laws. 
Higuchi Model for Non-Reservoir Polymeric Carriers 
Higuchi treated the drug release problem as a steady state, one 
dimensional diffusion process. Based upon FickÊs first law [11], the 
rate of diffusion of drug ܴ௧ (mole/s)for a non-biodegradable and 
non-swelling polymer matrices[12]is given by the following 
expression: 
R୲ ൌ  െSD
ୢC
ୢ୶
   (1) 
S is the cross sectional area (m2); D is the diffusion coefficient of 
the drug in the polymer matrix (m2/s); C is the concentration of the 
drug and x is the distance from solvent-matrix interface (Figure 5). 
 
 
 
Figure 5.Schematic presentation of the drug concentration-distance-profile after exposure to perfect sink conditions.࡯࢏࢔࢏ሺ࡯૙) is the initial drug 
concentration in the polymer matrix which is much higher than ࡯࢙ the solubility concentration of the drug in the matrix. X represents the distance 
from the matrix-medium interface, ࢾ is the thickness of the thin film. 
 
The boundary conditions are: 
CൌCୠK at xൌ0                                                                                                    
ሺ2ሻ 
CൌCୱ at xൌ Xሺ3ሻ 
ܥ௕ is the drug concentration in the release media and ܥ௦ is the 
solubility concentration of the drug in the matrix. C is the drug 
concentration in the polymer matrix. Perfect sink condition is 
assumed which implies that the concentration of drug in the 
polymer matrix is much higher than the drug concentration at the 
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matrix-medium interface (ܥ௕ܭሻ. K is the matrix-to-medium partition 
coefficient. The initial drug concentration inside the polymer matrix 
is much higher than its solubility concentration (by a factor of 10 or 
more). According to this assumption is takes a very long time for 
the excess amount of the drug concentration to dissolve at a 
distance x from the films surface. Therefore, the drug concentration 
at a distance „x‰ from the film at any time remains almost constant 
which results in pseudo steady state condition. In order to solve 
FickÊs law to obtain the diffusion coefficient we must know how the 
concentration profile of the drug looks like.One solution is to 
assume a linear concentration profile for the drug. Therefore we 
have: 
R୲ ൌ SD
ሺCSିCౘKሻ
Xሺ୲ሻ
(4) 
 
In order to solve the above equation we have: 
 
R୲ ൌ
ୢM౪
ୢ୲
ൌ  ୢ
ୢ୲
ሼቂC଴ െ
ଵ
ଶሺC౩ାCౘKሻ
ቃ SXሺtሻሽ     (5) 
 
whereܥ଴ሺܥ௜௡௜ሻis the total drug concentration. After substituting ܴ௧ 
in equation (5) with equation (4) and the followed by a series of 
integration, the final equation is written as: 
M୲ ൌ SሾDሺCୱ െ CୠKሻሺ2C଴ െ Cୱ െ CୠKሻtሿଵ/ଶ(6) 
 
It is assumed that the initial drug concentration is higher than its 
solubility concentration in the polymer matrix. Also, under sink 
conditions it is assumed that the drug concentration in the release 
medium is almost zero which means that: ܥ௕~0. When ܥ௦ ا ܥ଴: 
M୲ ൌ Sሾ2DCୱC଴tሿଵ/ଶ   (7) 
 
The above equation can also be further simplified to the following 
form: 
ܯ௧ ൌ ݇√ݐ ,                           where ݇
ൌ ܵඥ2ܦܥ௦ܥ଴                                                                                ሺ8ሻ 
It is obvious that total mass of drug released follows „square root of 
time‰ dependence.  
In all the above equations K is the partition function of the drug 
between the membrane and the reservoir. 
For the non-core-shell carriers with different geometries as shown 
in Figure 6, the mass of drug released shows much more 
complicated time dependence.  Roseman and Higuchi proposed 
the following implicit equations.  Here, the term implicit signifies 
that Mt cannot be isolated on the left hand side of the equation[13, 
14]. 
For spherical carriers: 
 
ܯ௧
ܯஶ
െ
3
2
ሾ1 െ ൬1 െ
ܯ௧
ܯஶ
ሻ
ଶ
ଷ൨
ൌ െ
3ܦ
ܴଶ
.
ܥ௦
ܥ଴
. ݐ                                                                            ሺ13ሻ 
 
For cylindrical carriers: 
ܯ௧
ܯஶ
൅ ൬1 െ
ܯ௧
ܯஶ
൰ ln ൬1 െ
ܯ௧
ܯஶ
൰
ൌ
4ܦ
ܴଶ
.
ܥ௦
ܥ଴
. ݐ                                                                               ሺ14ሻ 
 
 
 
Figure 6. Thin film, spherical and cylindrical geometries used to 
model drug release from non-reservoir devices (devices without a 
core-shell structure). 
If the initial concentration of the drug in the polymer matrix is 
homogeneously distributed at a value below the solubility 
concentration of the drug (ܥ଴ሻ, and the perfect sink conditions are 
still applied at the surface of the thin film, the drug concentration at 
a distance „x‰ from the surface of the thin film cannot be 
considered constant anymore and will vary with respect to time. In 
this case, FickÊs second law for one dimensional isothermal drug 
transport should be solved[15]: 
߲ܥ
߲ݐ
ൌ ܦ
߲ଶܥ
߲ݔଶ
                                                                                                                   
The solution to FickÊs second law with the above assumptions for 
thin film is [16, 17]: 
M౪
Mಮ
ൌ 4ሺୈ୲
ஔమ
ሻ
భ
మሼπି
భ
మ ൅ 2 ∑ ሺെ1ሻ୬ஶ୬ୀଵ ierfc
୬ஔ
ଶ√ୈ୲
ሽ ሺ9ሻ 
Razavilar et al. International Journal of Drug Delivery 5 (4) 362-378 [2013] 
 
PAGE | 367 |
 
 
The second term in brackets vanishes at small times therefore: 
M౪
Mಮ
ൌ 4ሺ ୈ୲
ஔమ஠
ሻ
భ
మ(10) 
The above equation is accurate for 
ெ೟
ெ¥
൑ 0.6 ሺshort time releaseሻ. According to Equation (10) 
which is obtained by using a pure „Fickian diffusion‰ approach; the 
release of drug again shows ݐଵ/ଶdependence. The same relation 
between fractional drug release and time was obtained according 
to HiguchiÊs approach discussed earlier. Therefore, the principal 
result is a square root time dependence of the drug transport. For 
thin films at long times, we have: 
ܯ௧
ܯஶ
ൌ 1 െ
8
ߨଶ
exp ቆെ
ߨଶܦݐ
ܮଶ
ቇ , ܮ
ൌ ߜ                                                                                         ሺ11ሻ 
In another study, the release rate of an anti-Parkinson drug from 
degrading polymer (PLGA matrix) was studied. During the time of 
the experiment, which was exactly 4 days, the changes in the 
volume of the polymer matrix was negligible; therefore, the polymer 
microspheres were considered as non-biodegradable implants. In 
their study, their experimental results showed a good fit with the 
following solution of FickÊs second law of diffusion: 
MಮିM౪
Mಮ
ൌ ଺
஠మ
∑ ଵ
୬మ
 exp ቀെ ୬
మ஠మ
Rమ
Dtቁஶ୬ୀଵ ሺ12ሻ 
where ܯ௧and ܯஶare the cumulative amounts of drug at time t 
and infinity; R is the radius of the sphere and D is the diffusion 
coefficient [18]. This model assumes perfect sink condition, the 
polymer matrix is considered to be a sphere and that the drug is 
distributed homogeneously initially. From the above equation, it is 
obvious that the amount of drug released at any time does not 
depend on polymer molecular weight and volume during the course 
of experiment. 
For spheres at short times after solving the above equation we 
have [19]: 
ܯ௧
ܯஶ
ൌ 6ሺ
ܦݐ
ߨݎଶ
ሻ
ଵ
ଶ െ
3ܦݐ
ݎଶ
,       
ܯ௧
ܯஶ
൏ 0.4                                                                                             ሺ16ሻ 
For spheres at long times, 
ܯ௧
ܯஶ
ൌ 1 െ
6
ߨଶ
exp ቆെ
ߨଶܦݐ
ݎଶ
ቇ,        
ܯ௧
ܯஶ
൐ 0.6                                                                                      ሺ17ሻ 
For cylinders at short times, 
ܯ௧
ܯஶ
ൌ 4ሺ
ܦݐ
ߨݎଶ
ሻ
ଵ
ଶ െ
ܦݐ
ݎଶ
,      
ܯ௧
ܯஶ
൑ 0.4                                                                                          ሺ18ሻ 
For cylinder at long times, 
ܯ௧
ܯஶ
ൌ 1 െ
4
ሺ2.405ሻଶ
exp ቆെ
ሺ2.405ሻଶܦݐ
ݎଶ
ቇ,      
ܯ௧
ܯஶ
൐ 0.6                                                                ሺ19ሻ 
Here, only radial diffusion is considered. 
HiguchiÊs Model for Reservoir Polymer Carriers 
The reservoir(or core-shell) structure is one that the drug 
molecules are in the core of the structure and are surrounded by a 
layer of polymer. This structure can also be prepared in different 
geometries as shown in Figure 7. 
 
 
Figure 7.Common reservoir (core-shell type) structures 
encapsulating drug molecules for drug delivery. 
HiguchiÊs assumption is used again here; the released drug in the 
shell is rapidly replaced by the excess amount of drug available in 
the core of the reservoir. This is in line with HiguchiÊs assumption 
that initial drug concentration is much higher than the solubility 
concentration of the drug in the polymer which means the drug 
concentration will not change as a function of time within the shell 
of the reservoir. Assuming perfect sink conditions, equations to 
describe the kinetics of drug release have been obtained for 
different geometries shown in Figure 7[19].  
For thin films, 
ܯ௧
ൌ  
ܵܦܭܥ௦
ܮ
. ݐ                                                                                                            
For spheres, 
ܯ௧ ൌ
4ߨܦܭܥ௦ݎ௢ݎ௜
ݎ௢ െ ݎ௜
. ݐ                                             ሺ21ሻ 
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For cylinders, 
ܯ௧
ൌ
2ߨܪܦܭܥ௦
ln ሺݎ௢ݎ௜
ሻ
. ݐ                                                                        ሺ22ሻ 
Perfect sink conditions are again provided in the surrounding bulk 
fluid. In the following models,ܥ଴ ا ܥ௦. Furthermore, there is no 
drug excess in the core which means that the released drug 
molecules are not replaced and the drug concentration at the inner 
membrane's surface decreases with time. For thin film 
ܯ௧
ܯஶ
ൌ 1 െ exp ൬െ
ܣܦܭݐ
ܸܮ
൰                                        ሺ23ሻ 
For spheres, 
ܯ௧
ܯஶ
ൌ 1
െ exp ሺെ
3ݎ଴ܦܭݐ
ሺݎ௜ሻଶݎ଴ െ ሺݎ௜ሻଷ
ሻ                              ሺ24ሻ 
For cylinders, 
ܯ௧
ܯஶ
ൌ 1 െ              ሺ25ሻ 
Applications of the above mentioned models for both non-reservoir 
and reservoir types drug delivery devices to analyze experimental 
data have been reported by Siepmann et al.[19]. 
Analytical Solutions 
HiguchiÊs model does have some limitations that are mainly due to 
the initial assumptions made to simplify the mathematical 
description of the systems. For example, the initial concentration of 
the drug should be at least 10 times higher than the solubility 
concentration of the drug in the matrix to ensure that the pseudo 
steady state condition applies. This assumption is not possible for 
drugs with high aqueous solubility which leads to the failure of 
HiguchiÊs model with an error more than 11% compared to the 
exact solution for the system [15]. In this case in practice we will 
not have a linear concentration profile anymore and the drug 
concentration at a distance „x‰ from the thin film surface will 
change with respect to time and will dissolve in the medium; 
therefore, FickÊs second law will apply and the concentration profile 
of drug is a Gaussian function (normal probability distribution) 
which could be obtained by solving FickÊs one dimensional law of 
diffusion for unsteady-state conditions: 
߲݂
߲ݐ
ൌ ܦ
߲ଶ݂
߲ݔଶ
                            െ ∞ ൏ ݔ ൏ ൅∞, ݐ
൐ 0                                                                          ሺ26ሻ 
The only assumption here is that the diffusion coefficient is not a 
function of the drug concentration. Initial condition is specified as: 
f(x, t=0) =݂ ଴ሺݔሻ. The function „f‰ is „concentration‰ as a function of 
x and t. 
The solution for the above equation is: 
݂ሺݔ, ݐሻ
ൌ න ଴݂ሺݔᇱሻሼ
1
√4ߨܦݐ
ାஶ
ିஶ
݁ି
ሺ௫ᇲି௫ሻమ
ସ஽௧ ሽ݀ݔᇱ                                                                
If we use the „Dirac Delta‰ function for ଴݂ we obtain: 
݂ሺ∆ݔ, ∆ݐሻ
ൌ
1
√4ߨܦ∆ݐ
݁ି
ሺ∆௫ሻమ
ସ஽∆௧                                                                                                  
Where ∆ݔ ൌ ݔ െ ݔ଴. 
As we can see in the above equation, the concentration profile of 
such a case is a Gaussian function that is not linear at all.  
Swelling Non-Reservoir Polymeric Carriers 
One major assumption of all of the aforementioned models is that 
the polymer matrix does not swell. However, in reality, swelling 
does take place in many polymer carriers. Almost all oral drug 
delivery carriers are non-reservoir, non-biodegradable but swell. 
These carriers are usually prepared by compressing a powder 
mixture of a hydrophilic polymer and drug into tablets.  
Power Law Model 
Peppas et al. modified HiguchiÊs model in order to consider the 
polymer swelling kinetics. According to equation (10), the first 60% 
of the fractional drug release can be explained by multiplying a 
constant by the square root of time. A simple and comprehensive 
equation can be used to model such drug release process which is 
called the power law[20]: 
M౪
Mಮ
ൌ at୬(29) 
In the above equation „a‰ is a constant which incorporates the 
structural and geometric characteristics of the drug delivery device 
and „n‰ is the release exponent which is indicative of the drug 
delivery mechanism. The power law is a very useful equation that 
was developed by „Peppas‰ at 1985. This model is not derived 
from solutions of FickÊs laws and is recognized as a semi-empirical 
equation. 
Case I and Case II drug release extremes have been studied by 
Alfrey et al [21]. Here, Case I refers to a Fickian diffusion process 
where the penetrant mobility is much slower than the segmental 
relaxation rate while Case II refers to a case where the penetrant 
mobility is much higher than the segmental relaxation rate. Case II 
applies to polymer matrices that swell.  When the exponent is 
between 0.5 and 1 for a thin film, the process is called anomalous 
transport. In order to better understand the different mechanisms of 
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drug transport through polymer matrices during swelling, the 
swelling interface number has been used to describe the balance 
between drug release and solvent (water) penetration into the 
polymer matrix: 
ܵௐ
ൌ
ߴߜ௧
ܦ
                                                                        ሺ30ሻ 
Where ߴ is the velocity of the polymer-moving front which depends 
on the solvent (water) diffusivity, D is the drug diffusion coefficient 
and ߜ௧ is the thickness of the swollen gel layer. 
According to the above equation if the drug diffusion coefficient is 
much lower than that of the solvent (water) (ܵௐ ب 1), solvent 
penetration will control the release pattern (i.e., swelling controlled 
transport). If the drug diffusion coefficient is much higher than the 
solvent (water) mobility (ܵௐ ا 1ሻ, drug diffusion will control the 
release pattern. 
In the power law equation, we can see that if the exponent is 0.5 
for a thin film the process is Fickian or Case I transport as 
mentioned before. On the other hand, if the exponent is 1, for a thin 
film the process, it is Case II transport that involves swelling of the 
polymer matrix and water uptake. For other geometries different 
exponent values corresponding to different drug release 
mechanisms and they can be found in literature [22, 23]. A list of 
different values for „n‰ is shown in Table 1for different geometries. 
One should be cautious about using the values in Table 1 because 
there are several assumptions used in the power law such as: 
perfect sink conditions and drug release at short time (60% of the 
drug is released). 
 
Table 1. Values of the exponent „n‰ for the power law equation 
Geometry CaseI, Fickian 
diffusion 
Anomalous 
transport 
Case II, 
swelling 
controlled 
transport 
Thin film n =0.5 0.5൏ n ൏
1.0 
n =1.0
cylinder n =0.45 0.45 ൏ ݊
൏ 0.89 
n =0.89
sphere n =0.43 0.43 ൏ ݊
൏ 0.89 
n =0.83
 
The well-known power law expression was used in a study to 
describe the drug release from simple swellable and erosion matrix 
systems in which degradation is confined to a thin surface layer of 
the polymer matrix[24]. In their study, the exponent (n) was used 
for the interpretation of the release mechanism from polymeric 
controlled drug release systems[25].  
Swelling and degradation of polymer matrices were studied in 
chitosan-polycarbophil complexes and hydrxypropylmethylcellulose 
containing a simple mixture of chitosan and polycarbophil powders 
[26]. The drugs used in this study were hydrochlorothiazide and 
ketoprofen. According to this study, the chitosanăpolycarbophil 
complex showed good swelling with low degradation and slower 
drug release compared to the other matrices containing different 
polymer material. The segment mobility in different polymer types 
affected the drug release kinetics during swelling. The power law 
was used to explain the drug release kinetics and different values 
for the exponent (n) were obtained.  
Obviously, the power law has its own limitations: 
The power law model still requires the model system to be in the 
perfect sink conditions. When a large volume of fluid surrounds a 
drug carrier, this assumption holds. Otherwise, the bulk 
concentration of drug would not be negligible. 
Although different values for „n‰ are specified here. For different 
geometries, the power law still lacks the ability to model 
pharmaceutically relevant geometries. As mentioned before, 
different parameters in the power law are used for thin films, 
spheres and cylinders which are usually not the exact geometries 
used for drug delivery devices in experiments. 
An insight to the underlying mechanism for drug release cannot be 
obtained by using the power law equation. 
Only one dimensional diffusion behavior is considered in the power 
law model. 
Other Swelling Models 
Mathematical modeling of swelling controlled polymeric systems 
presented by Lee[27]suggested that both swelling and mass 
erosion could be modeled using the same type of diffusion 
equations. Lee [28]considered time-dependent diffusion 
coefficients defined as: 
D୲
ൌ  ܦ௜ 
൅ ሺܦஶ െ ܦ௜ሻሾ1
െ expሺെ݇ݐሻሿ                                                  ሺ31ሻ 
ܦ௜ ൌ initial drug diffusion coefficient. 
Dஶ= drug diffusion coefficient in the swollen polymer after long 
time. 
The model equation was solved for a Non-reservoir type system 
where HiguchiÊ assumption fails; C₀ ª Cs: 
ܯ௧
ܯஶ
ൌ 1 െ ෍
8
ሺ2݊ ൅ 1ሻଶߨଶ
ஶ
௡ୀ଴
exp ሼെሺ݊ ൅ 0.5ሻଶߨଶሺ
ܦஶݐ
݈ଶ
൅
ܦஶ
݈݇ଶ
ሾ1 െ expሺെ݇ݐሻሿሻሽ                    ሺ32ሻ  
The analytical solution when HiguchiÊs assumption holds;C₀> Cs: 
ܯ௧
ܯஶ
ൌ  
1
ሺܥ଴ܥ௦
ሻerf ሺߛሻ
2
ߨଵ/ଶ
ሾ
ܦஶݐ
݈ଶ
െ ൬1 െ
ܦ௜
ܦஶ
൰
ܦஶ
݈݇ଶ
ሾ1
െ expሺെ݇ݐሻሿሿ
ଵ
ଶ                                                 ሺ33ሻ 
where 
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πଵ/ଶߛ expሺߛଶሻ erfሺߛሻ
ൌ
ܥ௦
ܥ଴ െ ܥ௦
                                                                                 ሺ34ሻ 
Siepmann and coworkers[29-32] developed a mathematical model 
to describe drug release from dissolving HPMC matrices. The 
„sequential layer‰ model considers diffusion, swelling, and polymer 
dissolution simultaneously. In the model, they considered transport 
both in the radial and the axial directions. The drug and water 
diffusion is based on FickÊs second law for cylindrical devices with 
concentration dependent diffusivities: 
 
ൌ
߲
߲ݎ
൬ܦ௞
߲ܥ௞
߲ݎ
൰ ൅
ܦܭ
ݎ
߲ܥ௞
߲ݎ
൅
߲
߲ݖ
൬ܦܭ
߲ܥ௞
߲ݖ
൰                                             ሺ35ሻ 
whereܥ௞ is the concentration of the diffusion speciesܦ௞ is the 
diffusion coefficient of the diffusion species. The diffusion 
coefficients of water and drug are estimated according to the free 
volume theory: 
ܦଵ
ൌ  ܦଵ௘௤ exp ൭െߚଵ ቆ1
െ
ܥଵ
ܥଵ௘௤
ቇ൱                                                            ሺ36ሻ 
ܦଶ
ൌ ܦଶ௘௤ exp ൭െߚଶ ቆ1
െ
ܥଶ
ܥଶ௘௤
ቇ൱                                                              ሺ37ሻ 
whereܦଵ௘௤and ܦଶ௘௤ are the diffusion coefficient of water and drug 
in the equilibrium swollen state of the system, ߚଵand ߚଶare 
dimensionless constants and ܥଵ௘௤ is the water concentration in the 
equilibrium-swollen state of the system. 
The reptation model is used to explain polymer dissolution[33, 34]. 
In this model, a dissolution rate constant is considered 
(݇ௗ௜௦௦ሻ which quantitatively characterizes a constant dissolution 
velocity per unit area: 
ܯ௉௧
ൌ  ܯ௉଴
െ ݇ௗ௜௦௦ܣ௧ݐ                                                        ሺ38ሻ 
whereܯ௉௧ and ܯ௉଴ are the dry matrix masses at times t=t and 
t=0. ܣ௧ is the system surface area at time t.Other models 
accounting for polymer dissolution have been summarized in a 
review article by Narasimhan[35]. 
Figure 8 shows the important parameters one needs to consider 
before developing a mathematical model for in-vitro drug release 
kinetics. 
 
 
Figure 8. Important steps thatare needed to consider before using or developing mathematical models to describe in-vitro drug release kinetics. 
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Biodegradable Non-Reservoir Polymeric Carriers 
Modeling degradation processes is obviously more challenging 
than all of the models described in the previous sections simply 
because such degradation models need to take the hydrolysis 
reaction into account as such reactions change the polymer 
structure, molecular weight and properties. The penetration of 
water molecules into the polymer matrices triggers hydrolysis 
reaction. As a result, degradation occurs which leads to the 
formation of monomers and oligomers that create pores or holes in 
the bulk structure of polymers. Depending on the type of polymer, 
two types of erosion behavior can happen: surface erosion and 
bulk erosion. If degradation occurs at a much longer time after 
diffusion of water molecules into the polymer matrices, all the 
polymer segments tend to degrade homogeneously resulting in 
bulk degradation. On the contrary, if polymer segments contain a 
considerable number of functional groups that can be hydrolyzed, 
the polymer will have a tendency to degrade really fast, this may 
cause degradation happen at a much faster rate than water 
diffusion resulting in surface degradation. Figure 9 illustrates both 
bulk and surface erosions. 
 
 
Figure 9 Illustration of bulk eroding matrix polymer (A) and surface 
eroding matrix polymer (B)  
 
Models  
In the following paragraphs we will introduce the major mechanistic 
models developed for drug release from degrading polymer 
matrices. In these models, the underlying mechanism of drug 
release is not clear. However, empirical models have been also 
developed to describe drug release from degrading polymer 
matrices based upon the assumption that the drug release process 
obeys zero order kinetics. Such models somewhat similar to the 
power law model lack the ability to give the drug release 
mechanisms. 
Hopfenberg [36]developed an empirical model from drug release 
from eroding polymers by assuming that the overall release 
process is controlled by a single zero order process. This overall 
process considers a combination of dissolution, swelling, and 
polymer chain scission. A general mathematical equation was 
derived, which is valid for thin films, cylinders, and spheres: 
ܯ௧
ܯஶ
ൌ 1 െ ሾ1
െ
ܭ଴ݐ
ܥ଴ܽ
ሿ௡                                                    ሺ39ሻ 
where n = 3, 2 and 1 for spheres, cylinders and thin films, 
respectively. Here, a is the radius of the sphere or cylinder or half 
thickness of thin film. ܥ଴is the initial drug concentration in the 
system. K0 is the equilibrium rate constant which has the units of 
concentration per time for a zero order kinetic process. This 
constant depends on the solution temperature, ionic strength and 
surface area of the matrix. Since in this model the drug release 
kinetics controls the overall kinetics, this model cannot be used for 
bulk eroding surfaces. This model can only be applied to surface 
eroding systems. 
During the course of degradation, the polymer molecular weight 
and mass change as a function of time that in turn causes the drug 
diffusivity as well. Therefore, in this process, the drug diffusion 
coefficient can no longer be considered as constant. For this 
purpose, equation (40) was used to determine the diffusion 
coefficient. In equation (40), Mw at a given time is calculated using 
equation (41). 
ܦெ௪ ൌ  ܦ଴ ൅
݇
ܯݓ
                                                                ሺ40ሻ 
If the degradation kinetics is described by a first order process 
(e.g., PLGA), Mw of the polymer at a given time is approximated 
by: 
ܯ௪,௧ ൌ ܯ௪,଴exp ሺെ݇ௗ௘௚t)                                                                                  
(41) 
whereܯ௪,଴is the initial polymer molecular weight, ݇ௗ௘௚is the first 
order degradation rate constant. 
By incorporating the time dependence of molecular weight into 
CrankÊs[17]diffusion model (equation 42)and KoizumiÊs[37] model 
(equation 43), one yields the following kinetics equation: 
ܯ௧
ܯஶ
ൌ 1
െ
6
ߨଶ
ሺ෍
1
݊ଶ
ஶ
௡ୀଵ
exp ቆെ
ܦ݊ଶߨଶݐ
ݎଶ
ቇ                   ሺ42ሻ 
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The above model can also be used when the drug initial 
concentration is smaller than its solubility concentration in the 
system. 
For KoizumiÊs model: 
ܳ
ൌ 4ߨܽଶ ൤ඥ2ሺܥ଴ െ ܥ௦ሻܥ௦ܦݐ
൅
4ܥ௦
9ܽ
൜
ܥ௦
ሺ2ܥ଴ െ ܥ௦ሻ
െ 3ൠ ܦݐ൨                                                            ሺ43ሻ 
wherea is the radius of a spherical particle.  
Equations (42) and (43) can only be used for bulk degradation 
cases because the degradation kinetics controls the overall 
kinetics. As mentioned before, surface erosion is considered when 
the drug diffusion controls the overall kinetics of the release 
process. 
One assumption in the models described in the „non-biodegradable 
polymers‰ sections is that the polymer matrix loaded with drug 
molecules is considered to be homogeneous. When degradation 
occurs to the polymer matrix, the matrix will become 
heterogeneous in terms of the distribution of the molecular weight 
of the polymer chains and pores created on the surface of 
matrices.  This obviously will affect the diffusivity of drug. If we 
consider other species such as water and acid being released 
during the course of polymer degradation, this adds complexity 
tothe required mathematical models. In particular, the diffusion 
coefficient of drug becomes a function of time and position in the 
matrix as well. These models are called „models of multiple release 
mechanisms‰ which were studied by Himmelstein and co-workers 
[38, 39].Joshi et al.[40-42] developed a model for thin film 
geometries to describe the drug release from surface erodible 
polymer matrices. Their model assumes perfect sink conditions 
and no changes in the total volume of the matrix. The following 
expression is used to describe this model: 
பC౟
ப୲
ൌ  ப
ப୶
ቂD୧ሺx, tሻ
பC౟
ப୶
ቃ ൅ Ԃ୧  i ൌ A, B, C, E(44) 
ܥ௜ and ܦ௜are the concentration and the diffusivity of species i, and 
ߴ௜ is the net sum of the degradation and synthesis of species i, and 
x is the space variable. In order to consider the effect of the 
degradation process on the diffusion coefficient, the diffusivity of all 
species is related to the extent of polymer hydrolysis according to 
the following expression: 
D୧ ൌ  D୧,଴ exp ൤
µ൫CD,బିCD൯
CD,బ
൨ ,    A, B, C, E   (45) 
ܦ௜,଴is the diffusion coefficient of species i when the polymer is not 
hydrolyzed, ܥ஽,଴  and ܥ஽ are the concentration of species i at time 
zero and t respectively, and ߤ is a constant.  
Charlier et al.[43]also developed a model for bulk eroding PLGA 
films. Assuming first-order polymer chain cleavage kinetics, 
݀ܯ
݀ݐ
ൌ െ݇ܯ                                                                              ሺ46ሻ 
ܯ
ൌ ܯ଴݁ି௞௧                                                                                                                                                ሺ47ሻ 
whereܯ଴is the initial polymer molecular weight, k is the 
degradation rate constant. 
With: 
ܦ
ܦ଴
ൌ
ܯ଴
ܯ
                                                                                                                         
ܦ ൌ ܦ଴݁ି௞௧                                                    ሺ49ሻ 
whereܦ଴ is the drug diffusion coefficient before degradation. 
Finally, an expression for drug release is obtained: 
ܳ
ൌ ܵ ඨ
2ܥ଴ܥ௦ܦ଴ሺ݁௞௧ െ 1ሻ
݇
మ
                                                    ሺ50ሻ 
whereܥ଴ is the initial drug concentration, ܥ௦ is the drug solubility in 
the matrix, S is the surface area of the film exposed to the medium. 
At short times, the above equation becomes HiguchiÊs equation: 
ܳ ൌ ܵඥܥ଴ܥ௦ܦ଴ݐ                                                ሺ51ሻ 
In other words, at short times, drug release is diffusion based and 
at long times, the drug release is affected by polymer degradation. 
Heller and Baker[44]developed a model that applies to bulk eroding 
polymers that undergo hydrolysis and are solubilized by conversion 
to small, water-soluble molecules. The Higuchi model was used as 
a basis: 
݀ܯ௧
݀ݐ
ൌ
ܣ
2
ሺ
2ܲܥ଴
ݐ
ሻ
ଵ
ଶ                                                     ሺ52ሻ 
where P is the permeability of the polymer to the drug, A is the 
surface area for both sides of the film and ܥ଴is the initial drug 
concentration in the polymer. According to HiguchiÊs model, the 
drug permeability was assumed to be constant but during 
degradation the drug permeability changes with respect to time: 
ܲ
଴ܲ
ൌ
Initial number of bonds
Number of remaining bonds
ൌ
ܰ
ܰ െ ܼ
                                                               ሺ53ሻ 
The bond cleavage order was assumed to be first order as shown 
in the following equation: 
ܼ݀
݀ݐ
ൌ ܭሺܰ െ ܼሻሺ54ሻ 
where K is the first order rate constant. 
After integration and substituting back into HiguchiÊs equation, it 
yields: 
݀ܯ௧
݀ݐ
ൌ
ܣ
2
ሾ
2 ଴ܲ expሺܭݐሻ ܥ଴
ݐ
ሿ
ଵ
ଶ                                              ሺ55ሻ 
It should be noted that factors such as polymer crystallinity, pH of 
the release medium, and physical size of the matrixalso affect 
hydrolysis reactions[45, 46]. 
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Nano-Sized Polymeric Carriers 
In general, nano-scale (10ă200 nm)polymer drug carriers are in the 
form of micelle. And they tend to be stable (no degradation and/or 
dissolution in blood stream) relative to the time scale associated 
with the drug release process. From a modeling perspective, 
micelles made up of block copolymers can be modeled as non-
biodegradable systems even though they are biodegradable. In 
fact, many studies of micellar carriers showed that drug 
encapsulated by micelles releases completely before the block 
copolymers degrades [47]. 
Owing to the length scale of the micelles, continuum models 
obviously lack the ability to describe the kinetics of drug release as 
the concentration of the drug in the micelle fluctuate significantly 
and it is not appropriate to assign a concentration profile (as what 
is done for continuum models) to such systems. Nevertheless, 
there are a few authors who have made the attempt to describe 
drug release from micelles using continuum models discussed 
before. For example, E. Khodaverdi et al.[48] have carried out an 
experimental in vitro release of naltrexone hydrochloride from block 
copolymer micelles at 37 ĈC under perfect sink conditions. They 
observed that the amount of drug released is related to the square 
root of time. HiguchiÊs diffusion model was used to describe the 
release process. Sutton et al., [49]have applied the technique of 
continuum model to study the whole micelle.  In particular, the 
authors treated the micelle as a sphere (see Figure10) and applied 
the Higuchi model for two time regimes: the first mathematical 
model, equation (58), is the Higuchi model for short time releases 
from the micelle (less than 75 hours) and the second model, 
equation (59), is the Higuchi model for long time release 
kinetics(more than 100 hours). 
 
ܵ ௗொ
ௗ௧
ൌ െ4ߨܽଶܦ ௗ௖
ௗ௔
                                                                                                                      
(56) 
where 
S: surface area 
D: diffusion constant of drug in polymer matrix. 
C: concentration of drug in radial distance. 
A: distance from the center of the sphere. 
Assuming that the release process is pseudo-steady state, they 
obtained: 
 
ܥ଴ሺܽ଴ଷ ൅ 2ܽᇱଷ െ 3ܽ଴ܽᇱଶሻ ൅ ܥ௦ ቀ4ܽᇱଶܽ଴ ൅ ܽ଴ଷ݈݊
௔బ
௔ᇲ
െ ܽ଴ଷ െ
ܽ଴ଶܽᇱ െ 2ܽᇱଷ൯ ൌ 6ܦܥ௦ܽ଴ݐ               (57) 
 
whereܥ௦ is the solubility of the drug in the permeating fluid: 
ܽ଴:radius of the spherical core of the micelle. 
ܽᇱ:distance of moving front from the center of the core at time t. 
ܥ଴:drug loading concentration. 
 
 
 
Figure10 .Schematic illustration of DOX loaded in a diblock 
copolymer micelle with the same corona block PEG and two 
different core blocks poly (D,L-lactide) or poly(e-caprolactone). d, 
hydrodynamic diameter of the micelle; 2Rg, PEG, thickness of 
corona. 
The fractional drug release is given by: 
 
ெሺ௧ሻ
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ᇲ
௔బ
ሻଷቁሿ                                    
(58) 
 
Figure 11.Schematic presentation of an „all atom‰ model on the left 
and a coarse-grained model on the right. According to the figure on 
the right, each sphere color represents a specific monomer inside 
the blocks of a block copolymer. These spheres represent larger 
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groups of atoms. In the „all atom‰ model each atom is presented 
with the same gray color 
where 
M (t): Mass of drug released at time t. 
ܯஶ ൌ Mass of drug released as the time approaches infinity. 
ܽ଴ ൌ
݀
2
െ ܴ௖௢௥௥௢௡௔ 
In the above equation,ܽᇱ is a function of time, t. The dynamic light 
scattering technique was used to measure d, and radius of gyration 
was used to find ܴ௖௢௥௥௢௡௔. After calculating ܽ଴ and knowing the 
ratio of 
஼ೞ
஼బ
,the value of ܽᇱcan beestimated by fitting the 
experimental data (fractions of drug released at each time) into 
equation (58). The diffusion coefficient was obtained by substituting 
the value for ܽᇱinto equation (57). As mentioned earlier, the above 
equations are valid for short time drug release from micelles. At 
long times, polymer degradation happens which causes the rest of 
the drug molecules to be released from the micelle as well. For 
long time release, the following Higuchi model is used: 
 
ெሺ௧ሻ
ெሺஶሻ
ൌ ܲሺ1 െ ଺
గమ
exp ቀିగ
మ஽௧
௔బ
మ ቁሻ                                                                                        
(59) 
 
Where P is the fraction of drug released at infinite time which was 
obtained by the extrapolation of the fraction of drugs released at 
the longest times of the measurements.  
If one examines critically what has been done to model the release 
kinetics from micelles, it seems that some important aspects are 
not included.  As mentioned, the first Higuchi model is used for 
kinetics of short time release from the micelle. According to the 
assumption of the Higuchi model (steady-state release), the 
concentration profile for the drug was assumed to change linearly 
with the distance from the solvent-polymer interface. Due to the 
very small size of the micelles (10 ă 200 nm in diameter) one 
cannot easily establish a concentration profile across the micelle. 
Another major assumption is that the diffusion takes place under 
pseudo-steady state conditions. This means that the initial 
concentration of the drug loaded into the core of the micelle is 
much higher than the solubility concentration of the drug in solvent. 
Given the size of the micelle core which is very small, the 
concentration of the drug loaded in the core cannot be much higher 
that the drug solubility in the solvent. In other words, an excess 
amount of drug in the polymer core does not exist. Therefore, the 
pseudo-steady state assumption fails. 
Finally, another assumption here is that the micelle is „spherical‰.  
However, other geometries do exist(e.g., rod-like micelles). 
Therefore, HiguchiÊs model for sphere would not be valid. 
Molecular Modeling 
As mentioned, use of continuum models for micelles is not suitable.  
In this regard, molecular dynamics (MD) simulation is probably the 
most suitable approach for studying the dynamics of the drug 
release process. The essence of MD simulation is that every atom 
in a molecular system is treated as a classical particle and the 
NewtonÊs equation of motion is solved under certain conditions 
(e.g., constant temperature, constant pressure, etc.).Analysis of the 
resultant trajectory (e.g., positions and velocities of the atoms as a 
function of time) will yield thermodynamic and transport properties 
of interest.  Since MD is a relatively mature simulation technique, 
there exist many excellent references on the topic [50-51].  In the 
context of drug release studies, MD can be used for two purposes.  
One is to simulate the micelle environment and calculate the 
corresponding flux of the drug molecules while the other is to 
calculate the diffusion coefficients of drug molecules diffusing in 
micron thick polymer films.  In terms of simulating micelles at the 
atomistic level, it is very expensive simply because a micelle 
normally contains more than 100,000 atoms (it contains tens of 
block copolymers, tens of drug molecules and tens of thousands 
water molecules). Therefore, certain level of coarse graining is 
needed to reduce the number of atoms in the system, thereby 
reducing computational costs (Figure 11).For example,[52-54] 
have developed a coarse-grain (CG) model for simulating 
phospholipids. Phospholipids have a hydrophilic head due to 
negatively charged phosphate groups and maybe other groups and 
their tail is hydrophobic due to lipids. Therefore, they have a high 
tendency to aggregate and form micelles in water, somewhat 
similar to the behavior of block copolymers in water. According to 
Klein and coworkersÊ method, one way to simulate the micelles is 
to represent each monomer in a block copolymer as a single 
spherical unit.    
 
By using this representation, both non-bonded and bonded 
interaction potentials are defined slightly different from all-atom 
simulations[55,56].The Harmonic potential used to describe the 
bonds between monomers is defined as: 
 ܷ௕௢௡ௗሺݎ௜௝)= 
(݇௕/2ሻሺݎ௜௝ െ ݎ଴ሻଶ                                                       ሺ60ሻ  
whereݎ଴ is the equilibrium bond distance. Another bonded potential 
is defined as: 
ܷ௕௘௡ௗ ൫ߠ௜௝௞൯
ൌ ݇ఏൣ1
െ cos൫ߨ
െ ߠ௜௝௞ሻ൧                                                                            ሺ61ሻ  
where݇ఏ is adjusted until the bond angle is correct (comparable 
with all-atom simulation parameters).Regarding the non-bonded 
interaction potential, the approach is slightly different. Obviously, 
one cannot use the same non-bonded interaction parameters 
obtained from the all-atom models to model interactions between 
larger groups of atoms. The Lennard-Jones potential functions 
differ from those of various atom pairs with wider potential wells in 
the case of the CG method. And such CG non-bonded interaction 
potentials are usually tested by comparing the computed density 
using such potentials with the corresponding experimental values. 
In addition, the radial distribution function of the block copolymer 
obtained from the all-atom method could be used as a reference. 
The non-bonded parameters ߪ and א are adjusted to reproduce 
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the first peak position and height of the radial distribution function. 
The non-bonded interaction potential function for CG atom pairs is 
described as follows: 
ܷ൫ݎ௜௝൯ ൌ ൬
15
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൰
א ሾሺ
ߪ
ݎ௜௝
ሻଽ െ ሺ
ߪ
ݎ௜௝
ሻ଺ሿ                                                                ሺ62ሻ 
Water molecules present in the micelles are considered to be a 
spherical and symmetric site called „W‰ which has LJ(6-4) 
interactions with each other and is made of „three‰ water 
molecules: 
ܷ൫ݎ௜௝൯ ൌ ൬
15
4
൰
א ሾሺ
ߪ
ݎ௜௝
ሻ଺
െ ሺ
ߪ
ݎ௜௝
ሻସ ሿ                                                                                   ሺ63ሻ 
To determine the diffusivity of drug molecules through the micelle, 
one method is to the Einstein relation. For this purpose, one needs 
to obtain the mean square displacement (MSD) of the center-of-
mass of individual drug molecules from the MD trajectory[52]. In 
the long time limit of normal diffusion, where the slope of the 
logarithmic plot of mean square displacement versus time (Figure 
)becomes constant, the center of mass diffusion coefficients is 
calculated from the Einstein relation [57]: 
 
ܦ ൌ  ଵ
଺
lim௧՜ஶ
ௗ
ௗ௧
ۃ|ܴሺݐሻ െ ܴሺ0ሻ|ଶۄ                                                                                             
(64) 
where R(t) and R(0) are vectors of displacement at time t and t=0. 
 
 
Figure 12. A schematic plot of mean square displacement against 
time. The slope of the plot at long times is related to the diffusion 
coefficient according to EinsteinÊs relation. 
 
Molecular dynamics simulation can also be used to calculate the 
drug diffusivity in micron thick polymer films.  This is useful, as the 
drug release profile requires knowledge of the drug diffusivity.  This 
is true for all the continuum models previously discussed. The 
challenge here is to obtain reliable diffusivity. The situation 
becomes more complicated when the polymer matrix degrades.  
This is because when degradation takes place, the diffusion at 
short times is considered to be Fickian diffusion and at long times, 
it is time dependent.  
Recently, Berhane et al.,[58]applied the MD technique to calculate 
diffusion coefficient of a drug namely 5-aminosalicyclic acid in a 
polymer thin film and found that the resultant value (5.7ൈ
10ି଺ܿ݉ଶ/ݏ) yielded an accurate prediction of the drug release 
from the delivery system (root mean square error of 5%).  The 
release profile was validated using experimental data from in vitro 
dissolution experiments.  One noteworthy point here is that the 
computation only used 3 hours of computational times. In another 
study, the diffusion coefficient of Nifedipinein phospholipid bilayer 
was calculated using an all atom molecular dynamics 
simulation[59]. In addition to the diffusion coefficient, the authors 
were able to gain insight into the detailed interactions between the 
drug molecule and the membrane. Experimental permeability 
values and computed diffusion coefficients were compared in 
literature [60]to investigate the diffusion coefficient of Theophylline 
and Aspirin molecules in PVA membranes. Both experimental and 
simulation data showed that Aspirin exhibited lower diffusivity than 
Theophylline due to stronger intermolecular interactions between 
Aspirin and PVA membrane. Many researchers have emphasized 
on the advantages of using molecular dynamics simulations to 
avoid experimental estimation of diffusivity that is usually time-
consuming and expensive. For example, to design a gel for a 
specific drug delivery application, Dutta et al.,[61] used molecular 
dynamics simulations to calculate the cross-linking density of 
polymers which affect swelling and release of drug molecules. The 
authors specifically emphasized the advantage of molecular 
dynamics simulation over continuum modeling and experimental 
methods as molecular dynamics directly addresses the 
intermolecular interactions between drug and polymers which are 
crucial for designing the gels of interest. 
Summary 
Continuum in vitro drug release models such as HiguchiÊs model, 
various variations of it and other complex mathematical models 
were discussed. When the initial drug concentration in a polymer 
carrier is lower than its solubility concentration, HiguchiÊs model 
tends to fail with an error of about 11% compared to the exact 
solution of the diffusion equations. This occurs when drug is highly 
soluble in the aqueous solution. Although the power law is a more 
comprehensive model for describing drug release kinetics, it still 
has its own limitations and one of them is not able to provide the 
release mechanism. 
Improvements to the continuum models in fact have been very 
useful for obtaining the fractional drug release profile vs. time that 
is commonly done in experimental studies. These models are 
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normally used to investigate a proper „fit‰ for the experimental 
measurements of drug release. In all the major in vitro drug release 
models, knowledge of the drug diffusivity in the polymer carrier is 
important to determine the fractional drug release profile. In this 
regard, molecular dynamics simulation is a powerful tool for 
estimating the required diffusivity.  The molecular level simulation 
can provide information about the underlying mechanism for drug 
release from polymer matrices.  
If drug release occurs in a nano-sized micelle, none of the 
discussed continuum models could describe the kinetics of drug 
release accurately. For such small systems, molecular dynamics 
simulation is a suitable tool to study the motion of molecules under 
certain conditions of temperature, pressure and system size. 
Measurement of drug diffusivity in the micelle environment is 
obviously not a trivial task.  However, diffusivity of drug molecules 
can be readily calculated using EinsteinÊs equation.  
Acknowledgements 
Funding from Natural Science and Engineering Research Council 
of Canada is gratefully acknowledged. 
  
 
References 
[1]. S.D.Bruck, Problems and artifacts in the 
evaluation of polymeric materials for 
medical uses,Biomaterials, 1 (1980) 
103-107. 
[2]. Y.W.Chien, B.E.Cabana, 
S.E.Mares,Novel drug delivery systems: 
fundamentals, developmental concepts, 
biomedical assessments, M. 
Dekker,14(1982) 633. 
[3]. R.Langer, Implantable controlled release 
systems, Pharm Ther, (1983) 21-35. 
[4]. R.Langer, Invited Review Polymeric 
Delivery Systems For Controlled Drug 
Release, Chemical Engineering 
Communications, 6(1980) 1-48. 
[5]. R.Langer, Medical Applications of 
Controlled Release, CRC Press, FL, 2 
(1986). 
[6]. G.S. Kwon, Polymeric micelles for 
delivery of poorly water soluble 
compounds, Drug Carrier Systems, 20 
(2003) 357-403. 
[7]. M.D. Allen, A.Eisenberg, Nano-
engineering block copolymer aggregates 
for drug delivery, Colloids Surf., B 
Biointerfaces, 16 (1999) 3-27. 
[8].  
[9]. [8] A.Lavasanifar, G.S.Kwon, 
Poly(ethylene oxide)-block-poly(-amino 
acid) micelles for drug delivery, Adv 
Drug Deliv Rev., 54 (2002) 169-190. 
[10]. H.A.Kataoka, Y.Nagasaki, Block 
copolymer micelles for drug delivery: 
design, characterization and biological 
significance, Adv Drug Deliv Rev., 47 
(2001) 113-131. 
[11]. S.N.H.Aerts, M.A.R.Meier, B.B.P. Staal, 
M.Rasa,U.S.Schubert, Detailed 
Characterization and Selected Micellar 
Drug Encapsulation Behavior, 
Macromolecules, 26 (2005) 1918-1924. 
[12]. A. Fick, On liquid diffusion,Membr Sci., 
100 (1995) 33-38. 
[13]. T. Higuchi, Rate of release of 
medicaments from ointment bases 
containing drugs in suspensions, Pharm 
Sci., 50 (1961) 874-875. 
[14]. W.I.Higuchi, T.J. Roseman, Release of 
medroxyprogesterone acetate from a 
silicone polymer, Pharm Sci. , 59 (1970) 
353-357. 
[15]. T.J. Roseman, Release of steroids from 
a silicone polymer, Pharm Sci. , 61 
(1972) 46-50. 
[16]. P. Lee, Diffusional release of a solute 
from a polymeric matrix-approximate 
analytical solutions, Membr Sci. , 7 
(1980) 255-275. 
[17]. J. Crank, The mathematics of diffusion, 
Oxford University Press Inc., New York, 
(1956) 1-32. 
[18]. J. Crank, The mathematics of diffusion, 
Oxford University Press Inc., New York, 
(1956) 1-32. 
[19]. P.S. E. D'Aurizio, L. S. Cerasa, M. 
Vacca, L. Brunetti, G. Orlando, A. 
Chiavaroli, R. J. Kok, W. E. Hennink, 
and A. Di Stefano, Biodegradable 
microspheres loaded with an anti-
parkinson prodrug: an in vivo 
pharmacokinetic study, Mol 
Pharmaceutics, 8 (6) (2011) 2408-2415. 
[20]. J. Siepmann, Modeling of diffusion 
controlled drug delivery, Controlled 
Release, 161 (2012) 351-362. 
[21]. G.W. Sinclair, N.A.Peppas, Analysis of 
non-Fickian transport in polymers using 
simplified exponential expressions, 
Membr Sci., 17 (1984) 329-331. 
[22]. G.E.Alfrey,W.G.Lloyd, Diffusion in 
glassy polymers, Polym Sci C., 12 
(1966) 249-261. 
[23]. P.L. Ritger, N.A.Peppas,A simple 
equation for decription of solute 
release:Fickian and non-Fickian release 
from non-swellable devices in the form 
of slabs spheres,cylinders or discs, 
ControlledRelease, 5 (1987) 23-26. 
[24]. R. Beker, Controlled Release of 
Biologically Active Agents, John Wiley & 
Sons, New York, 2(1987). 
[25]. W.C. Z. Lu, J.H.Hamman, Chitosan-
polycarbophil interpolyelectrolyte 
complex as a matrix former for 
controlled release of poorly water-
soluble drugs I in vitro evaluation, Drug 
Development and Industrial Pharmacy, 
36(5) (2010) 539-546. 
[26]. N.A. Peppas, Analysis of Fickian and 
non-Fickian drug release from polymers, 
Pharm Acta Helv, 60 (1985). 
[27]. W.C. Z. Lu, J.H.Hamman, Chitosan-
polycarbophil interpolyelectrolyte 
Razavilar et al. International Journal of Drug Delivery 5 (4) 362-378 [2013] 
 
PAGE | 377 |
 
 
complex as a matrix former for 
controlled release of poorly water-
soluble drugs I: in vitro evaluation, Drug 
Development and Industrial Pharmacy, 
36(5) (2010) 539-546. 
[28]. P.I.Lee, Diffusional release of a solute 
from a polymeric matrix·approximate 
analytical solutions, Membr Sci., 7 
(1980) 255-275. 
[29]. P.I.Lee, Interpretation of drug-release 
kinetics from hydrogel matrices in terms 
of time-dependent diffusion coefficients, 
American Chemical Society, Washington 
DC, 348(1987) 71-83. 
[30]. J.Siepmann, R.Bodmeier, N.A.Peppas, 
HPMC-matrices for controlled drug 
delivery: a new model combining diff 
usion, swelling and dissolution 
mechanisms and predicting the release 
kinetics, Pharm Res., 16 (1999) 1748-
1756. 
[31]. J.Siepmann, M.Sriwongjanya, 
N.A.Peppas, R.Bodmeier, A new model 
describing the swelling and drug release 
kinetics from hydroxypropyl 
methylcellulose tablets, Pharm Sci., 88 
(1999) 65-72. 
[32]. J.Siepmann, Hydrophilic matrices for 
controlled drug delivery: an improved 
mathematical model to predict the 
resulting drug release kinetics (the 
„sequential layer‰ model), Pharm Res., 
17 (2000) 1290-1298. 
[33]. J.Siepmann, N.A.Peppas, 
Understanding and predicting drug 
delivery from hydrophilic matrix tablets 
using the „sequential layer‰ model, 
Pharm Res., 19 (2002) 306-314. 
[34]. B.Narasimhan,N.A.Peppas, On the 
importance of chain reptation in models 
of dissolution of glassy polymers, 
Macromolecules, 29 (1996) 3283-3291. 
[35]. J.Siepmann, Modeling of drug release 
from delivery systems based on 
hydroxypropyl methylcellulose (HPMC), 
Adv Drug Del Rev., 48 (2001) 139-157. 
[36]. B.Narasimhan, Mathematical models 
describing polymer dissolution: 
consequences for drug delivery, Adv 
Drug Deliv Rev., 48 (2001) 195-210. 
[37]. Hopfenberg. H.B, Controlled release 
from erodible slabs, cylinders, and 
spheres, American Chemical Society, 
Washington DC,ACS Symposium series 
33, 1976. 
[38]. Panomsuk.S.P,T.Koizumi, Release of 
medicaments from spherical matrices 
containing drug in suspension: theoritical 
aspects, Int J Pharm., 116 (1995) 45-49. 
[39]. K.J.Himmelstein, A. Joshi, Dynamics of 
controlled release from bioerodible 
matrices, ControlledRelease, 15 (1991) 
95-104. 
[40]. K.J.Himmelstein, A.G.Thombre, A 
simultaneous transport-reaction model 
for controlled drug delivery from 
catalyzed bioerodible polymer matrices, 
AICHE., 31 (1985) 759-766. 
[41]. A.G.Thombre, Theoritical aspects of 
polymer biodegradation: mathematical 
modeling of drug release and acid-
catalyzed poly(ortho-
ester)biodegradation, M.Vert, J.Feijen, 
A.Albertsson, G.Scott, 
E.Cheillini,Biodegradable polymers and 
plastics, Redwood Press, (1992) 214-
228. 
[42]. A.Joshi, K.J.Himmelstein, Dynamics of 
controlled release from bioerodible 
matrices, Controlled Release, 15 (1991) 
95-104. 
[43]. A.G.Thombre, K.J.Himmelstein, A 
simultaneous transport-reaction model 
for controlled drug delivery from 
catalyzed bioerodible polymer matrices, 
AIChE, 31 (1985) 759-766. 
[44]. B.Lederc,A.Charlier,G.Couarraze, 
Release of mifepristone from 
biodegradable matrices: experimental 
and theoretical evaluations, Int J 
Pharm., 200 (2000) 115-120. 
[45]. R.W.Baker, J.Heller, Theory and 
practice of controlled drug delivery from 
bioerodible polymers, R.W.Baker, 
Controlled release of bioactive materials, 
Academic Press, New York, (1980) 1-
18. 
[46]. A. Frank, Factors affecting the 
degradation and drug-release 
mechanism of poly (lactic acid) and poly 
[(lactic acid)-co-(glycolic acid)], Polym 
Int., 54 (2005) 36-46. 
[47]. Z.R.Shen, J.H. Zhu, L.T. Wu, S.L.Yang, 
In vitro degradation of polylactide and 
poly (lactide-co-glycolide) microspheres, 
Appl Polym Sci., 43 (1991) 2099-2106. 
[48]. S.Y.Kim, J.H.Kim, Drug-release kinetics 
of MPEG/PLLA block copolymer 
micelles with different PLLA block 
lengths, Appl Polym Sci., 82 (2001) 
2599-2605. 
[49]. F.S.Mirzazadeh, E.Khodaverdi, 
S.A.Mohajeri, F.Ganji, G.Zohuri, 
F.Hadizadeh, Preparation and 
investigation of sustained drug delivery 
systems using an injectable, 
thermosensitive, in situ forming hydrogel 
composed of PLGAăPEGăPLGA, 
PharmSciTech., 13 (2012) 590-600. 
[50]. S.Wang, D.Sutton, N.Nasongkla, J.Gao, 
E.E.Dormidontova, Doxorubicin and b-
lapachone release and interaction with 
micellar core materials: experiment and 
modeling, Experimental Biology and 
Medicine, 232 (2007) 1090-1099. 
[51]. M. P. Allen and D. J. Tildesly, Computer 
Simulation of Liquids, Oxford University 
Press, New York, 1987. 
[52]. D. Frenkel and B. Smit, Understanding 
Molecular Simulation, Academic Press, 
New York, 2002. 
[53]. J. Lin, Zhu, J., Chen, T., Lin, S., Cai, C., 
Zhang, L., Zhuang, Y., Wang, X., Drug 
releasing behavior of hybrid micelles 
containing polypeptide triblock 
copolymer. , J. Biomaterials, 30 (2009) 
108-117 
[54]. X.D. Guo, Tan, J.P.K., Kim, S.H., Zhang, 
L.J., Zhang, Y., Hedrick, J. H., Yang, 
Y.Y., Qian, Y., Computational studies on 
self-assembled paclitaxel structures: 
Templates for hierarchical block 
copolymer assemblies and sustained 
drug release. , J. Biomaterials, 30 (2009) 
6556-6563. 
[55]. J.C.S. Shelley, M. Y.; Reeder, R. C.; 
Bandyopadhyay, S.; Klein, M. L. , J. 
Phys.  Chem., 105 (2001). 
Razavilar et al. International Journal of Drug Delivery 5 (4) 362-378 [2013] 
 
PAGE | 378 |
 
 
[56]. S.K. Nielsen, M. L., In Bridging time 
scales: Molecular simulations for the 
next decade, Berlin, Germany, 2002. 
[57]. S.L. Nielsen, C. F.; Srinivas, G.; Klein, 
M. L., J. Chem. Phys., 119 (2003). 
[58]. R.L. Goetz, R. , J. Chem. Phys., 108 
(1998). 
[59]. N.H. Berhane, Nyquist, C., Haghighi, K., 
Corvalan, C., Keshavarzian, A., 
Campanella, O., Rickus, J., Farhadi, A., 
A multi-scale stochastic drug release 
model for polymer-coated targeted drug 
delivery systems, Journal of Controlled 
Release, 110 (2006) 314-322. 
[60]. S.M.D. ]. C.E. Holy, J.E. Davies, M.S. 
Shoichet., In vitro degradation of a novel 
poly(lactide-co-glycolide) 75/25 foam, 
Biomaterials, 20 (1999) 1177ă1185. 
[61]. Encyclopedia of biopharmaceutical 
statistics, Informa Health Care, New 
York, 2003. 
[62]. R.C. Dutta, Rai, B., Molecular Dynamics 
Study of Drug Diffusion In Hydrogels : 
Effect of Cross-Linking, in:  AICHE 2011. 
 
 
 
 
 
